Soligenix, Inc. (SNGX) Thursday reported positive preliminary top-line results from the Phase 2a study of SGX302 for the treatment of mild-to-moderate psoriasis.
In the Cohort 2 of the study, 2 out of 4 patients treated with SGX302 reached a disease status of "Almost Clear" represented by an Investigator Global Assessment (IGA) score of 1, which is considered the standard clinical measure for treatment success in psoriasis.
Additionally, the Psoriasis Activity and Severity Index (PASI) score, another measure of treatment success, for patients in Cohort 2 had a mean drop of about 50% over the 18-week treatment.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.